Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

Mark Reacher; Ben Warne; Neville Q. Verlander; Ashley Popay; Lucy Reeve; Nicholas K. Jones; Kyriaki Ranellou; Nyaradzai Sithole; Rory Carpenter; Angharad Everden; Elizabeth Jarman; Ali Khalid; Kyle Lam; Chloe Myers; Shuhui Ren; Kathryn J. Rolfe; Tommy Sutton; Silvana Christou; Callum Wright; Saher Choudhry; Maria Zambon; Clare Sander; Hongyi Zhang; Hamid Jalal

doi:10.1016/j.jinf.2023.01.004

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

Mark Reacher^*, Ben Warne, Neville Q. Verlander, Ashley Popay, Lucy Reeve, Nicholas K. Jones, Kyriaki Ranellou, Nyaradzai Sithole, Rory Carpenter, Angharad Everden, Elizabeth Jarman, Ali Khalid, Kyle Lam, Chloe Myers, Shuhui Ren, Kathryn J. Rolfe, Tommy Sutton, Silvana Christou, Callum Wright, Saher ChoudhryMaria Zambon, Clare Sander, Hongyi Zhang, Hamid Jalal

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

Original language	English
Pages (from-to)	256-308
Number of pages	53
Journal	Journal of Infection
Volume	86
Issue number	3
DOIs	https://doi.org/10.1016/j.jinf.2023.01.004
Publication status	Published - Mar 2023

Bibliographical note

Publisher Copyright:
© 2023 The British Infection Association

Keywords

Historic Cohort study
Influenza A (H3N2) in-patient mortality
Influenza B
Logistic regression
Multiplex PCR
Multivariable logistic regression
PCR

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jinf.2023.01.004

Fingerprint

Dive into the research topics of 'Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons'. Together they form a unique fingerprint.

Cite this

Reacher, M., Warne, B., Verlander, N. Q., Popay, A., Reeve, L., Jones, N. K., Ranellou, K., Sithole, N., Carpenter, R., Everden, A., Jarman, E., Khalid, A., Lam, K., Myers, C., Ren, S., Rolfe, K. J., Sutton, T., Christou, S., Wright, C., ... Jalal, H. (2023). Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons. Journal of Infection, 86(3), 256-308. https://doi.org/10.1016/j.jinf.2023.01.004

@article{b8baf70b63e24bab98b1d1bf9be81fd6,

title = "Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons",

abstract = "Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.",

keywords = "Historic Cohort study, Influenza A (H3N2) in-patient mortality, Influenza B, Logistic regression, Multiplex PCR, Multivariable logistic regression, PCR",

author = "Mark Reacher and Ben Warne and Verlander, {Neville Q.} and Ashley Popay and Lucy Reeve and Jones, {Nicholas K.} and Kyriaki Ranellou and Nyaradzai Sithole and Rory Carpenter and Angharad Everden and Elizabeth Jarman and Ali Khalid and Kyle Lam and Chloe Myers and Shuhui Ren and Rolfe, {Kathryn J.} and Tommy Sutton and Silvana Christou and Callum Wright and Saher Choudhry and Maria Zambon and Clare Sander and Hongyi Zhang and Hamid Jalal",

note = "Publisher Copyright: {\textcopyright} 2023 The British Infection Association",

year = "2023",

month = mar,

doi = "10.1016/j.jinf.2023.01.004",

language = "English",

volume = "86",

pages = "256--308",

journal = "Journal of Infection",

issn = "0163-4453",

publisher = "W.B. Saunders Ltd",

number = "3",

}

Reacher, M, Warne, B, Verlander, NQ, Popay, A, Reeve, L, Jones, NK, Ranellou, K, Sithole, N, Carpenter, R, Everden, A, Jarman, E, Khalid, A, Lam, K, Myers, C, Ren, S, Rolfe, KJ, Sutton, T, Christou, S, Wright, C, Choudhry, S, Zambon, M, Sander, C, Zhang, H & Jalal, H 2023, 'Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons', Journal of Infection, vol. 86, no. 3, pp. 256-308. https://doi.org/10.1016/j.jinf.2023.01.004

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons. / Reacher, Mark; Warne, Ben; Verlander, Neville Q. et al.
In: Journal of Infection, Vol. 86, No. 3, 03.2023, p. 256-308.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

AU - Reacher, Mark

AU - Warne, Ben

AU - Verlander, Neville Q.

AU - Popay, Ashley

AU - Reeve, Lucy

AU - Jones, Nicholas K.

AU - Ranellou, Kyriaki

AU - Sithole, Nyaradzai

AU - Carpenter, Rory

AU - Everden, Angharad

AU - Jarman, Elizabeth

AU - Khalid, Ali

AU - Lam, Kyle

AU - Myers, Chloe

AU - Ren, Shuhui

AU - Rolfe, Kathryn J.

AU - Sutton, Tommy

AU - Christou, Silvana

AU - Wright, Callum

AU - Choudhry, Saher

AU - Zambon, Maria

AU - Sander, Clare

AU - Zhang, Hongyi

AU - Jalal, Hamid

PY - 2023/3

Y1 - 2023/3

N2 - Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

AB - Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.

KW - Historic Cohort study

KW - Influenza A (H3N2) in-patient mortality

KW - Influenza B

KW - Logistic regression

KW - Multiplex PCR

KW - Multivariable logistic regression

KW - PCR

UR - http://www.scopus.com/inward/record.url?scp=85149379725&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2023.01.004

DO - 10.1016/j.jinf.2023.01.004

M3 - Letter

C2 - 36646142

AN - SCOPUS:85149379725

SN - 0163-4453

VL - 86

SP - 256

EP - 308

JO - Journal of Infection

JF - Journal of Infection

IS - 3

ER -

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18 influenza seasons

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this